The Discounted Cash Flow (DCF) valuation of Tarsus Pharmaceuticals, Inc. (TARS) is (164.47) USD. With the latest stock price at 61.29 USD, the upside of Tarsus Pharmaceuticals, Inc. based on DCF is -368.3%.
Based on the latest price of 61.29 USD and our DCF valuation, Tarsus Pharmaceuticals, Inc. (TARS) is a sell. selling TARS stocks now will result in a potential gain of 368.3%.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| WACC / Discount Rate | 6.1% - 8.0% | 7.1% |
| Long-term Growth Rate | 3.0% - 5.0% | 4.0% |
| Fair Price | (448.51) - (102.65) | (164.47) |
| Upside | -831.8% - -267.5% | -368.3% |